OpGen Receives Frost & Sullivan New Product Innovation Award
News Aug 24, 2011
The annual Frost & Sullivan awards spotlight “best-in-class” companies based on excellence in managing growth, innovation and leadership, and are selected utilizing Frost & Sullivan’s global research organization of 1,800 analysts and consultants monitoring 300 industries and 250,000 companies.
“We are very pleased that Frost & Sullivan has recognized OpGen’s accomplishments in the successful development and commercialization of the Argus® Whole Genome Mapping System,” commented Doug White, CEO of OpGen. “Our recent success includes providing rapid and accurate whole genome maps of the German E. coli outbreak genome and a growing number of customers and publications that cite the value of incorporating whole genome maps to produce high quality de novo reference sequences.”
OpGen’s growing customer base includes high-profile genome centers such as Beijing Genome Institute and Wellcome Trust Sanger Institute as well as a number of research labs, bio-defense, government labs and public health institutions.
The New Product Innovation Awards in North America are presented to companies in a variety of industries that demonstrate excellence in the following categories: innovative element of the product, complimentary product leverage provided by the new product’s leading-edge technologies, value added features/benefits, increased customer ROI and customer acquisition or market penetration potential. Past recipients of Best Practice Awards include organizations such as Life Technologies, Bayer Diagnostics and Phillips Healthcare.
“The New Product Innovation Award recognizes the most innovative, market-changing technologies in the life science community,” notes industry analyst Christi Bird. “We expect OpGen’s Argus® System to become a vital tool in sequencing laboratories to drive efficiency and reduce costs of genome finishing.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE